Eli Lilly drug candidate trial sees major weight loss, knee pain relief
In a phase 3 trial, Eli Lilly’s experimental drug retatrutide delivered an average 28.7% weight loss and reduced pain among adults with obesity or overweight and knee osteoarthritis. The trial recruited 445 participants and divided them equally to receive retatrutide 9 milligrams, retatrutide 12 milligrams or a placebo for 68 weeks, according to a Dec. […]
Can Eli Lilly Sustain Its Obesity Momentum as Newer Players Emerge?
Eli Lilly and Company LLY is one of the two companies that dominate the booming cardiometabolic space, driven by its successful GLP-1 therapies — Mounjaro for diabetes and Zepbound for weight loss, both comprising the same ingredient, tirzepatide, a dual GIP/GLP-1 RA. Despite facing strong competition from Novo Nordisk’s NVO semaglutide medicines, Ozempic for diabetes and Wegovy […]
Can GLP-1s Help Fat Cats Lose Weight? The First Clinical Trial Testing the Drugs for Weight Loss in Felines Has Begun
San Francisco-based pharmaceutical company OKAVA is investigating an implant that slowly releases a GLP-1 medication for up to six months
Can Intuitive Surgical Weather GLP-1 Drag on Bariatric Surgery?
Intuitive Surgical ISRG faces a persistent headwind in one of its historically important U.S. procedure categories, namely bariatric surgery. For six consecutive quarters, domestic bariatric volumes have declined in the high single digits, a trend the company directly links to the rapid adoption of GLP-1 weight-loss drugs. Management confirmed that bariatric now represents less than […]
Lilly’s Next-Gen Obesity Shot Shows Best-In-Class Weight Loss In Study
Lilly’s Next-Gen Obesity Shot Shows Best-In-Class Weight Loss In Study Shares of Eli Lilly are higher in premarket trading after the company unveiled blowout topline results for its next-generation obesity drug retatrutide, which delivered more than 23% weight loss over 68 weeks – the strongest performance yet for a late-stage obesity trial. Adult patients in […]
The 11 Biggest GLP-1 Myths, Busted by Expert Dietitians
If you’ve spent any time on social media lately, you might have seen conflicting claims about GLP-1 weight loss medications. One post says they’ll completely kill your appetite. Another warns about scary side effects. Someone else declares losing weight this way is “cheating.” With all the noise out there, it’s tough to know what’s actually […]
Inspire Medical (INSP) Fell Due to Multiple Headwinds
Mairs & Power, an investment advisor, released the third-quarter 2025 investor letter for the “Mairs & Power Small Cap Fund.” A copy of the letter can be downloaded here. The market’s concentration persists in 2025, with a few dominant mega-cap stocks tied to artificial intelligence (AI) driving most of the favorable outcomes. The fund returned […]
Here’s How GLP-1 Affected MGP Ingredients (MGPI) in Q3
Mairs & Power, an investment advisor, released the third-quarter 2025 investor letter for the “Mairs & Power Small Cap Fund.” A copy of the letter can be downloaded here. The market’s concentration persists in 2025, with a few dominant mega-cap stocks tied to artificial intelligence (AI) driving most of the favorable outcomes. The fund returned […]
STAT+: Pharmalittle: We’re reading about Lilly’s new obesity drug, E.U. pharma rules, and much more
Top of the morning to you, and a fine one it is. Although quite chilly so far, the clear, blue skies and warm sunshine are a heartening elixir for a busy day ahead. To cope, we are brewing fresh cups of stimulation. Our choice today is chocolate raspberry. As always you are invited to join […]
STAT+: Lilly’s next-gen obesity drug delivers major weight loss in Phase 3 trial, but with many discontinuations
Eli Lilly’s next-generation obesity drug led to what appears to be the most weight loss seen so far in a late-stage trial, but rates of side effects were high and many participants discontinued the treatment, including people who felt they were losing too much weight. In a 68-week Phase 3 study of patients with obesity […]